Celgene Corp (NASDAQ:CELG)

CAPS Rating: 5 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Recs

0
Player Avatar line70day (< 20) Submitted: 11/27/2012 3:33:35 PM : Outperform Start Price: $82.22 CELG Score: +2.87

Some insiders traded hedge funds based on inside information and were caught the Co. withdrew its application to expand its application for the use of Revlimid in Europe made purchases of small Co's at substantial gains

Featured Broker Partners


Advertisement